Don’t Miss TipRanks’ Half Year Sale
- Take advantage of TipRanks Premium for 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
CSPC Pharmaceutical Group ( (HK:1093) ) has issued an update.
CSPC Pharmaceutical Group announced that its drug CPO301 has received the third Fast Track designation from the U.S. FDA for treating advanced non-small cell lung cancer (NSCLC) without EGFR mutations. This designation highlights the drug’s promising clinical efficacy and is expected to expedite its development and registration globally, potentially enhancing CSPC’s position in the oncology market.
The most recent analyst rating on (HK:1093) stock is a Buy with a HK$10.26 price target. To see the full list of analyst forecasts on CSPC Pharmaceutical Group stock, see the HK:1093 Stock Forecast page.
More about CSPC Pharmaceutical Group
CSPC Pharmaceutical Group is a company in the pharmaceutical industry, focusing on the development of innovative drugs. It specializes in creating treatments for various diseases, with a significant emphasis on oncology products.
YTD Price Performance: 23.25%
Average Trading Volume: 145,397,173
Technical Sentiment Signal: Buy
Current Market Cap: HK$67.73B
Find detailed analytics on 1093 stock on TipRanks’ Stock Analysis page.